Aggrastat tirofiban data

Preliminary analysis of one of three Phase III trials showed that at the 30-day primary end point, Aggrastat combined with heparin and aspirin reduced the incidence of adverse outcomes in angioplasty patients, but not at a statistically significant level.

The reduction was significant at 2 and 7 days, with reductions of 38 percent and 27 percent, respectively, versus standard therapy. ...